SCHEDULE: Vanguard Group Discloses 5.47% Stake in Relay Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 5.47% in Relay Therapeutics Inc.'s common stock.

Summary

• The Vanguard Group holds an aggregate beneficial ownership of 9,379,851 shares of Relay Therapeutics Inc. Common Stock.
• This ownership represents 5.47% of the class of securities.
• Vanguard has sole voting power over 0 shares, shared voting power over 85,367 shares, sole dispositive power over 9,185,595 shares, and shared dispositive power over 194,256 shares.
• The filing was made by The Vanguard Group, an investment adviser based in Malvern, PA.
• The issuer, Relay Therapeutics Inc., is located at 399 Binney Street, 2nd Floor, Cambridge, MA, 02139.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership report (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects. It is a factual disclosure of an investment stake.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of institutional ownership, indicating a significant passive investment by The Vanguard Group in Relay Therapeutics Inc., a company likely operating within the biotechnology or pharmaceutical sector. It does not provide specific insights into broader industry trends or competitive dynamics beyond the ownership stake itself.

Stakeholder Impact

• Shareholders: The filing indicates a significant institutional investor, The Vanguard Group, holds a 5.47% stake, which can be viewed as a vote of confidence or a stable long-term holding by a major fund manager. Vanguard's clients are the ultimate beneficial owners.

Key Dates

Keywords

Relay Therapeutics Inc., The Vanguard Group, Common Stock, Beneficial Ownership, Schedule 13G, Investment Adviser, Biotechnology, Pharmaceuticals